Histone deacetylase inhibitor treatment induces ‘BRCAness’ and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells

There is an unmet need to develop new, more effective and safe therapies for the aggressive forms of triple negative breast cancers (TNBCs). While up to 20% of women under 50 years of age with TNBC harbor germline mutations in BRCA1, and these tumors are sensitive to treatment with poly(ADP) ribose...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Ha, Kyungsoo, Fiskus, Warren, Choi, Dong Soon, Bhaskara, Srividya, Cerchietti, Leandro, Devaraj, Santhana G. T., Shah, Bhavin, Sharma, Sunil, Chang, Jenny C., Melnick, Ari M., Hiebert, Scott, Bhalla, Kapil N.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Impact Journals LLC 2014
Pynciau:
Research Paper
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4170637/
https://ncbi.nlm.nih.gov/pubmed/25026298
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg